These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 7541854)
1. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group. Gingell JC; Knönagel H; Kurth KH; Tunn UW J Urol; 1995 Aug; 154(2 Pt 1):399-401. PubMed ID: 7541854 [TBL] [Abstract][Full Text] [Related]
2. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Radlmaier A; Eickenberg HU; Fletcher MS; Fourcade RO; Reis Santos JM; van Aubel OG; Bono AV Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703 [TBL] [Abstract][Full Text] [Related]
3. Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review. el Etreby MF J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):565-72. PubMed ID: 7682838 [TBL] [Abstract][Full Text] [Related]
4. Effects of estrogen deprivation on human benign prostatic hyperplasia. Schweikert HU; Tunn UW; Habenicht UF; Arnold J; Senge T; Schulze H; Schröder FH; Blom JH; Ennemoser O; Horniger W J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):573-6. PubMed ID: 7682839 [TBL] [Abstract][Full Text] [Related]
5. Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. Habenicht UF; Tunn UW; Senge T; Schröder FH; Schweikert HU; Bartsch G; el Etreby MF J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):557-63. PubMed ID: 7682837 [TBL] [Abstract][Full Text] [Related]
6. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia. el Etreby MF; Nishino Y; Habenicht UF; Henderson D J Androl; 1991; 12(6):403-14. PubMed ID: 1722797 [TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy for benign prostatic hyperplasia in the 90's. Ekman P J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721 [TBL] [Abstract][Full Text] [Related]
8. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies. Habenicht UF; el Etreby MF J Androl; 1991; 12(6):395-402. PubMed ID: 1722796 [TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors. Nishino Y; Schneider MR; Michna H; el Etreby MF J Steroid Biochem; 1989; 34(1-6):435-7. PubMed ID: 2533949 [TBL] [Abstract][Full Text] [Related]
10. Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results. Habenicht UF; Schwarz K; Schweikert HU; Neumann F; el Etreby MF Prostate; 1986; 8(2):181-94. PubMed ID: 2419882 [TBL] [Abstract][Full Text] [Related]
11. Estrogens and benign prostatic hyperplasia: rationale for therapy with aromatase inhibitors. Henderson D Ann Med; 1991 Aug; 23(3):201-3. PubMed ID: 1718322 [No Abstract] [Full Text] [Related]
12. [Aromatase inhibitors in the medical treatment of benign prostatic hypertrophy]. Tunn UW; Goldschmidt AJ J Urol (Paris); 1993; 99(6):307. PubMed ID: 7516374 [No Abstract] [Full Text] [Related]
13. Selective inhibition of androstenedione-induced prostate growth in intact beagle dogs by a combined treatment with the antiandrogen cyproterone acetate and the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione (1-methyl-ADD). Habenicht UF; el Etreby MF Prostate; 1989; 14(4):309-22. PubMed ID: 2473459 [TBL] [Abstract][Full Text] [Related]
14. The function and the role of aromatase inhibitors in the treatment of BPH. el Etreby MF; Habenicht UF Prog Clin Biol Res; 1994; 386():209-30. PubMed ID: 7528389 [No Abstract] [Full Text] [Related]
16. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955 [TBL] [Abstract][Full Text] [Related]
17. Synergic inhibitory effects of the aromatase inhibitor 1-methyl-androsta-1, 4-diene-3, 17-dione and the antiandrogen cyproterone acetate on androstenedione-induced hyperplastic effects in the prostates of castrated dogs. Habenicht UF; el Etreby MF Prostate; 1987; 11(2):133-43. PubMed ID: 2444953 [TBL] [Abstract][Full Text] [Related]
18. Induction of estrogen-related hyperplastic changes in the prostate of the cynomolgus monkey (Macaca fascicularis) by androstenedione and its antagonization by the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione. Habenicht UF; Schwarz K; Neumann F; el Etreby MF Prostate; 1987; 11(4):313-26. PubMed ID: 2446299 [TBL] [Abstract][Full Text] [Related]
19. Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism. Brodie AM; Son C; King DA; Meyer KM; Inkster SE Cancer Res; 1989 Dec; 49(23):6551-5. PubMed ID: 2479464 [TBL] [Abstract][Full Text] [Related]
20. Role of estrogens in human benign prostatic hyperplasia. Sciarra F; Toscano V Arch Androl; 2000; 44(3):213-20. PubMed ID: 10864369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]